生物制剂-话题@MedSci

#生物制剂#

122篇内容 | 4582人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1825978, encodeId=135418259e8ea, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Aliment Pharm Therap:中度至重度溃疡性结肠炎：托法替布vs生物制剂, objectType=article, longId=131750, objectId=cb93131e509e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb93131e509e, replyNumber=0, likeNumber=86, createdTime=2019-01-28, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb93131e509e, moduleTitle=Aliment Pharm Therap:中度至重度溃疡性结肠炎：托法替布vs生物制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb93131e509e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825973, encodeId=d2e618259e305, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂, objectType=article, longId=123375, objectId=cf7e1233e57b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf7e1233e57b, replyNumber=0, likeNumber=77, createdTime=2018-01-08, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf7e1233e57b, moduleTitle=FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf7e1233e57b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825986, encodeId=95af182598619, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=患者报告结局相比客观炎性标记物对生物制剂治疗RA患者病假的影响更为重要, objectType=article, longId=144553, objectId=3957144553e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3957144553e4, replyNumber=0, likeNumber=110, createdTime=2019-03-12, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3957144553e4, moduleTitle=患者报告结局相比客观炎性标记物对生物制剂治疗RA患者病假的影响更为重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3957144553e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825970, encodeId=098e18259e0d5, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=J Rheumatol：生物制剂联合狄诺塞麦治疗类风湿关节炎的重症感染发生率, objectType=article, longId=120959, objectId=02061209599e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02061209599e, replyNumber=0, likeNumber=73, createdTime=2018-05-07, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02061209599e, moduleTitle=J Rheumatol：生物制剂联合狄诺塞麦治疗类风湿关节炎的重症感染发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02061209599e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825976, encodeId=a84e18259e67b, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Kidney int：生物制剂治疗类风湿性关节炎对肾脏有影响么？, objectType=article, longId=129511, objectId=6b6212951122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b6212951122, replyNumber=0, likeNumber=61, createdTime=2018-05-17, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b6212951122, moduleTitle=Kidney int：生物制剂治疗类风湿性关节炎对肾脏有影响么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b6212951122)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825969, encodeId=50141825969a3, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=IBD：轻-中度溃疡性结肠炎中使用激素和生物制剂的注意事项, objectType=article, longId=116308, objectId=f82a1163086c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f82a1163086c, replyNumber=0, likeNumber=58, createdTime=2018-05-21, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f82a1163086c, moduleTitle=IBD：轻-中度溃疡性结肠炎中使用激素和生物制剂的注意事项, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f82a1163086c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825975, encodeId=d2b418259e50f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批, objectType=article, longId=125572, objectId=5dcf1255e2c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dcf1255e2c7, replyNumber=0, likeNumber=127, createdTime=2018-04-07, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dcf1255e2c7, moduleTitle=西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dcf1255e2c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825984, encodeId=d30318259844b, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼, objectType=article, longId=141331, objectId=b2131413318b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2131413318b, replyNumber=0, likeNumber=87, createdTime=2018-12-09, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2131413318b, moduleTitle=西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2131413318b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825981, encodeId=4f6818259816f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=JCC：生物制剂的再诱导与剂量间隔缩短相比，在治疗克罗恩失应答上效果相同且更便宜。, objectType=article, longId=133255, objectId=3d011332559c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d011332559c, replyNumber=0, likeNumber=37, createdTime=2018-08-13, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d011332559c, moduleTitle=JCC：生物制剂的再诱导与剂量间隔缩短相比，在治疗克罗恩失应答上效果相同且更便宜。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d011332559c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825962, encodeId=0f8b182596239, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Semin Arthritis Rheum：RA患者结核感染后可否继续使用生物制剂, objectType=article, longId=99886, objectId=c40399886f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c40399886f5, replyNumber=0, likeNumber=69, createdTime=2017-05-27, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c40399886f5, moduleTitle=Semin Arthritis Rheum：RA患者结核感染后可否继续使用生物制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c40399886f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825967, encodeId=bb24182596e95, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Gastroenterology：克罗恩病术后使用生物制剂的困境, objectType=article, longId=107099, objectId=4d6210e09926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d6210e09926, replyNumber=0, likeNumber=79, createdTime=2018-06-24, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d6210e09926, moduleTitle=Gastroenterology：克罗恩病术后使用生物制剂的困境, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d6210e09926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825965, encodeId=33bc182596520, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Lancet：生物制剂tildrakizumab：牛皮癣“克星”，治疗效果超神奇！, objectType=article, longId=100984, objectId=0b2d100984ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b2d100984ce, replyNumber=0, likeNumber=62, createdTime=2017-07-21, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b2d100984ce, moduleTitle=Lancet：生物制剂tildrakizumab：牛皮癣“克星”，治疗效果超神奇！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b2d100984ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825966, encodeId=197518259660e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Lancet：治疗类风湿关节炎的新型生物制剂和小分子抑制剂的新近进展。, objectType=article, longId=101445, objectId=0017101445df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0017101445df, replyNumber=0, likeNumber=69, createdTime=2017-08-05, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0017101445df, moduleTitle=Lancet：治疗类风湿关节炎的新型生物制剂和小分子抑制剂的新近进展。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0017101445df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825968, encodeId=4d88182596853, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Arthritis Rheum:生物制剂治疗类风湿关节炎安全性探索, objectType=article, longId=110783, objectId=59df110e830d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59df110e830d, replyNumber=0, likeNumber=70, createdTime=2018-02-08, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59df110e830d, moduleTitle=Arthritis Rheum:生物制剂治疗类风湿关节炎安全性探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59df110e830d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825963, encodeId=75b41825963ac, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=银屑病关节炎免疫机制及生物制剂治疗的进展, objectType=article, longId=100527, objectId=238c10052ef9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=238c10052ef9, replyNumber=0, likeNumber=68, createdTime=2018-01-25, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=238c10052ef9, moduleTitle=银屑病关节炎免疫机制及生物制剂治疗的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=238c10052ef9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825964, encodeId=336818259641c, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=生物制剂tildrakizumab：牛皮癣“克星”, objectType=article, longId=101036, objectId=ea8210103664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea8210103664, replyNumber=0, likeNumber=64, createdTime=2018-03-14, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea8210103664, moduleTitle=生物制剂tildrakizumab：牛皮癣“克星”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea8210103664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825957, encodeId=5046182595e6f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=JAMA Dermatol：生物制剂可减少银屑病患者的冠状动脉疾病进展, objectType=article, longId=72959, objectId=22ebe295900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ebe295900, replyNumber=0, likeNumber=72, createdTime=2016-07-16, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ebe295900, moduleTitle=JAMA Dermatol：生物制剂可减少银屑病患者的冠状动脉疾病进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ebe295900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825958, encodeId=8829182595819, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=2016BSR/BHPR指南——生物制剂治疗中轴脊椎关节炎（包括强制性脊柱炎）发布, objectType=article, longId=76149, objectId=b082e61491a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b082e61491a, replyNumber=0, likeNumber=0, createdTime=2017-05-05, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b082e61491a, moduleTitle=2016BSR/BHPR指南——生物制剂治疗中轴脊椎关节炎（包括强制性脊柱炎）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b082e61491a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825954, encodeId=4515182595438, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=RA患者不同生物制剂的住院感染风险是否不同？, objectType=article, longId=65003, objectId=1bc4650034d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bc4650034d, replyNumber=0, likeNumber=0, createdTime=2016-06-06, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bc4650034d, moduleTitle=RA患者不同生物制剂的住院感染风险是否不同？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bc4650034d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1825956, encodeId=324c1825956bb, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=突破药丸：生物制剂新时代的致胜给药战略, objectType=article, longId=71401, objectId=73dfe140155, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73dfe140155, replyNumber=0, likeNumber=65, createdTime=2016-12-08, rootId=0, userName=bluefate121, userId=93e223, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73dfe140155, moduleTitle=突破药丸：生物制剂新时代的致胜给药战略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73dfe140155)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生物制剂

2020-05-29发表于威斯康星

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

Aliment Pharm Therap:中度至重度溃疡性结肠炎：托法替布vs生物制剂

2019-01-28

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂

2018-01-08

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

患者报告结局相比客观炎性标记物对生物制剂治疗RA患者病假的影响更为重要

2019-03-12

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

J Rheumatol：生物制剂联合狄诺塞麦治疗类风湿关节炎的重症感染发生率

2018-05-07

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

Kidney int：生物制剂治疗类风湿性关节炎对肾脏有影响么？

2018-05-17

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

IBD：轻-中度溃疡性结肠炎中使用激素和生物制剂的注意事项

2018-05-21

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批

2018-04-07

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼

2018-12-09

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

JCC：生物制剂的再诱导与剂量间隔缩短相比，在治疗克罗恩失应答上效果相同且更便宜。

2018-08-13

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

Semin Arthritis Rheum：RA患者结核感染后可否继续使用生物制剂

2017-05-27

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

Gastroenterology：克罗恩病术后使用生物制剂的困境

2018-06-24

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

Lancet：生物制剂tildrakizumab：牛皮癣“克星”，治疗效果超神奇！

2017-07-21

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

Lancet：治疗类风湿关节炎的新型生物制剂和小分子抑制剂的新近进展。

2017-08-05

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

Arthritis Rheum:生物制剂治疗类风湿关节炎安全性探索

2018-02-08

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

银屑病关节炎免疫机制及生物制剂治疗的进展

2018-01-25

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

生物制剂tildrakizumab：牛皮癣“克星”

2018-03-14

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

JAMA Dermatol：生物制剂可减少银屑病患者的冠状动脉疾病进展

2016-07-16

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

2016BSR/BHPR指南——生物制剂治疗中轴脊椎关节炎（包括强制性脊柱炎）发布

2017-05-05

仁医06 (审核中...)

前往app查看评论内容

#生物制剂#

RA患者不同生物制剂的住院感染风险是否不同？

2016-06-06

bluefate121 (审核中...)

前往app查看评论内容

#生物制剂#

突破药丸：生物制剂新时代的致胜给药战略

2016-12-08

科室
- - 订阅+
  - 更多科室
工具
服务